US Centers for Disease Control and Prevention, Global Immunization Division,1600 Clifton Road (MS E-05), Atlanta, GA 30333, United States of America.
Bull World Health Organ. 2009 Dec;87(12):955-9. doi: 10.2471/BLT.08.061556. Epub 2009 Oct 1.
Poliovirus transmission remained a public health challenge in western Uttar Pradesh, India in late 2005 and early 2006. In 2006, the India Expert Advisory Group for Polio Eradication concluded that, given the peak incidence of polio among children 6 to 12 months of age, a targeted birth dose of oral polio vaccine may be necessary to interrupt intense poliovirus transmission in high risk areas.
The Government of Uttar Pradesh, the National Polio Surveillance Project and the United Nations Children's Fund (UNICEF) implemented a pilot birth-dose project aimed at identifying and vaccinating all newborns with a dose of oral polio vaccine within 72 hours of birth in an effort to evaluate operational feasibility and potential impact on population immunity.
The project was piloted in Moradabad district: zone 7 in Moradabad City (urban setting), Kunderki block (rural setting) and in select birthing hospitals.
Between July 2006 and February 2007, 9740 newborns were identified, of which 6369 (65%) were vaccinated by project personnel within 72 hours of birth. Project coverage (for total newborns vaccinated) ranged from 39% (in zone 7) to 76% (in Kunderki block) of the estimated number of newborns vaccinated during previous supplemental immunization activities.
Birth-dose coverage among newborns was lower than expected. Expansion costs were estimated to be high, with marginal impact. The project, however, provided opportunities to strengthen newborn tracking systems which have increased the number of newborns and young infants vaccinated during supplemental immunization activities and enrolled in routine programmes.
2005 年末至 2006 年初,印度北方邦西部的脊髓灰质炎病毒传播仍然是公共卫生面临的挑战。2006 年,印度脊髓灰质炎专家咨询小组得出结论,鉴于儿童 6 至 12 个月大时脊髓灰质炎发病率最高,为了阻断高危地区脊髓灰质炎病毒的高强度传播,可能需要对新生儿进行有针对性的口服脊髓灰质炎疫苗基础免疫。
北方邦政府、国家脊髓灰质炎监测项目和联合国儿童基金会(儿基会)实施了一项试点出生剂量项目,目的是在新生儿出生后 72 小时内,确定并为所有新生儿接种一剂口服脊髓灰质炎疫苗,以评估其运作可行性和对人群免疫力的潜在影响。
该项目在莫拉达巴德区试点:莫拉达巴德市 7 区(城市环境)、昆德基布洛克(农村环境)和选定的几家分娩医院。
2006 年 7 月至 2007 年 2 月期间,共发现 9740 名新生儿,其中 6369 名(65%)由项目人员在出生后 72 小时内接种了疫苗。项目覆盖率(按接种疫苗的新生儿总数计算)从之前补充免疫活动中估计接种的新生儿数的 39%(7 区)到 76%(昆德基布洛克)不等。
新生儿的基础免疫接种率低于预期。预计扩大成本很高,影响有限。然而,该项目为加强新生儿跟踪系统提供了机会,从而增加了补充免疫活动期间和常规方案中接种疫苗的新生儿和婴幼儿人数。